March 2020 Legislative & Regulatory Briefing: Articles include CMS Issues Contract Year 2021 and 2022 Medicare Advantage and Part D Proposed Rule; AMCP Shares CMS Resources for COVID-19 Response; AMCP Submits Comments on Drug Importation on Proposals
AMCP Develops 2020 Policy and Advocacy Focus Areas; CMS Issues CY 2021 Advanced Notice for MA Capitation Rates and Part C and Part D Payment Policies – Part II; CMS Issues CY 2021 and 2022 Medicare Advantage and Part D Proposed Rule; CMS Releases New Guidance on Medicaid Waiver Flexibility
AMCP Submits Comments to HHS OIG on Proposed Revisions to AKS Safe Harbors; AMCP to Comment on White House Proposal to Allow Drug Importation; FDA Issues Draft Guidance on Interchangeable Insulin; AMCP Invited to Participate in Pharmaceutical Quality Workshop
Trump Administration Issues Proposed Rule Allowing Importation; House Passes H.R. 3 Drug Pricing Bill on Party-Line Vote; AMCP Submits Letter to House on 21st Century Cures 2.0; Stephen Hahn, MD, Confirmed as New FDA Commissioner; FDA Issues Draft Guidance on Interchangeable Insulin
AMCP Joins Stakeholder Letter to SAMHSA on Proposed Rule to Update 42 CFR Part 2; AMCP Seeks Input on Proposed Rule to Change Anti-Kickback Statute; CMS Issues Price Transparency Rules
for Hospital and Insurers
HHS OIG Issues Proposed Rule to Remove Regulatory Barriers to Care Coordination, Value-based Care; Congress Continues Work on Drug Pricing Bills in House and Senate;
House Speaker Nancy Pelosi Introduces Drug Pricing Bill H.R.3; Hill Days: AMCP Takes Message to
House and Senate Offices; SAMHSA Issues New Proposed Rule to Modernize 42 CFR Part 2
